AccScience Publishing / JCBP / Online First / DOI: 10.36922/jcbp.4238
Submit to JCBP
Cite this article
15
Download
466
Views
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
ORIGINAL RESEARCH ARTICLE

Mapping structural and research trends in schizophrenia and metabolic syndrome: A bibliometric analysis

Simin Yi1 ,  Feihong Weng1 ,  Nannan Liu1,2 ,  Yanzhe Li1,2 ,  Doudou Zheng1,2 ,  Chenghao Lu1,2 ,  Shen Li1,2*
Show Less
1 Institute of Mental Health, Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, Tianjin, China
2 Psychoneuromodulation Center, Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, Tianjin, China
JCBP 2024, 2(4), 4238 https://doi.org/10.36922/jcbp.4238
Submitted: 14 July 2024 | Accepted: 19 September 2024 | Published: 23 October 2024
© 2024 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Download PDF
Cite
XML
Abstract

An escalating body of research is directing its focus toward schizophrenia (SZ) patients who grapple with metabolic syndrome (MS). By employing bibliometric approach, this study comprehensively assessed the research landscape and prevailing trends within SZ and MS-related fields. All relevant publications related to SZ and MS were systematically extracted from the Web of Science Core Collection database up to August 15, 2023. Data analysis was conducted using software such as VOSviewer, Citespace, Pajek, and R software, as well as online bibliometric website. A total of 2651 publications on SZ and MS were collected, with the United States emerging as the primary contributor (n = 1970). Pivotal international research collaborations were observed, notably between the United States and the United Kingdom (n = 56). The French Research Universities exhibited prolific contributions. Schizophrenia Research emerged as the foremost influential journal in this domain. In addition to “schizophrenia” and “metabolic syndrome,” keywords such as “atypical antipsychotics” and “body weight” featured prominently within the literature. Our study underscores the growing significance of SZ with MS research. These findings collectively shed light on the dynamic and evolving nature of research pertaining to SZ and MS, reflecting an unwavering commitment to unravel the complexities and implications inherent in these intertwined domains.

Keywords
Schizophrenia
Metabolic syndrome
Bibliometric analysis
Atypical antipsychotic
Olanzapine
Funding
This work was financially supported by the National Natural Science Foundation of China (82371512), Tianjin Key Medical Discipline (Specialty) Construction Project (TJYXZDXK-033A), Tianjin Municipal Education Commission Scientific Research Program Project (2022KJ265), and Foundation of Tianjin Health Commission for Young Scholars (TJWJ2021QN064).
Conflict of interest
Shen Li is an Editorial Board Member of this journal but was not in any way involved in the editorial and peer-review process conducted for this paper, directly or indirectly. Separately, other authors declared that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.
References
  1. Jauhar S, Johnstone M, McKenna PJ. Schizophrenia. Lancet. 2022;399:473-486. doi: 10.1016/s0140-6736(21)01730-x

 

  1. Valery KM, Prouteau A. Schizophrenia stigma in mental health professionals and associated factors: A systematic review. Psychiatry Res. 2020;290:113068. doi: 10.1016/j.psychres.2020.113068

 

  1. Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global epidemiology and burden of schizophrenia: Findings from the global burden of disease study 2016. Schizophr Bull. 2018;44:1195-1203. doi: 10.1093/schbul/sby058

 

  1. Fahed G, Aoun L, Bou Zerdan M, et al. Metabolic syndrome: Updates on pathophysiology and management in 2021. Int J Mol Sci. 2022;23:786. doi: 10.3390/ijms23020786

 

  1. Guest PC. Insulin resistance in schizophrenia. Adv Exp Med Biol. 2019;1134:1-16. doi: 10.1007/978-3-030-12668-1_1

 

  1. Zhang Y, Wang Q, Reynolds GP, et al. Metabolic effects of 7 antipsychotics on patients with schizophrenia: A short-term, randomized, open-label, multicenter, pharmacologic trial. J Clin Psychiatry. 2020;81:19m12785. doi: 10.4088/JCP.19m12785

 

  1. Goldfarb M, De Hert M, Detraux J, et al. Severe mental illness and cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol. 2022;80:918-933. doi: 10.1016/j.jacc.2022.06.017

 

  1. Ninkov A, Frank JR, Maggio LA. Bibliometrics: Methods for studying academic publishing. Perspect Med Educ. 2022;11:173-176. doi: 10.1007/s40037-021-00695-4

 

  1. Chen C, Song M. Visualizing a field of research: A methodology of systematic scientometric reviews. PLoS One. 2019;14:e0223994. doi: 10.1371/journal.pone.0223994

 

  1. Wang J, Shahzad F. A Visualized and scientometric analysis of health literacy research. Front Public Health. 2021;9:811707. doi: 10.3389/fpubh.2021.811707

 

  1. Liu X, Zhao S, Tan L, et al. Frontier and hot topics in electrochemiluminescence sensing technology based on CiteSpace bibliometric analysis. Biosens Bioelectron. 2022;201:113932. doi: 10.1016/j.bios.2021.113932

 

  1. Van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84:523-538. doi: 10.1007/s11192-009-0146-3

 

  1. Huggett S. Journal bibliometrics indicators and citation ethics: A discussion of current issues. Atherosclerosis. 2013;230:275-277. doi: 10.1016/j.atherosclerosis.2013.07.051

 

  1. Chen MY, Zhang Q, Liu YF, et al. Schizophrenia and oxidative stress from the perspective of bibliometric analysis. Front Psychiatry. 2023;14:1145409. doi: 10.3389/fpsyt.2023.1145409

 

  1. Sun HL, Bai W, Li XH, et al. Schizophrenia and inflammation research: A bibliometric analysis. Front Immunol. 2022;13:907851. doi: 10.3389/fimmu.2022.907851

 

  1. Gao Q, Zhang C, Wang J, et al. The top 100 highly cited articles on osteoporosis from 1990 to 2019: A bibliometric and visualized analysis. Arch Osteoporos. 2020;15:144. doi: 10.1007/s11657-020-0705-z

 

  1. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19-32. doi: 10.1016/j.schres.2005.07.014

 

  1. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276. doi: 10.1093/schbul/13.2.261

 

  1. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223. doi: 10.1056/NEJMoa051688

 

  1. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696. doi: 10.1176/ajp.156.11.1686

 

  1. Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. Lancet. 2019;394:939-951. doi: 10.1016/s0140-6736(19)31135-3

 

  1. Penninx BWJ, Lange SMM. Metabolic syndrome in psychiatric patients: Overview, mechanisms, and implications. Dialogues Clin Neurosci. 2018;20:63-73. doi: 10.31887/DCNS.2018.20.1/bpenninx

 

  1. Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: A systematic review and network meta-analysis. Lancet Psychiatry. 2020;7:64-77. doi: 10.1016/s2215-0366(19)30416-x

 

  1. Li M, Weng PF. A Bibliometrics analysis on academic influence of Chinese journal of integrated traditional and Western medicine. Chin J Integr Med. 2021;27:148-152. doi: 10.1007/s11655-020-3434-7

 

  1. Deng Z, Wang H, Chen Z, Wang T. Bibliometric analysis of Dendritic Epidermal T Cell (DETC) research from 1983 to 2019. Front Immunol. 2020;11:259. doi: 10.3389/fimmu.2020.00259

 

  1. Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: A systematic review and meta-analysis. World Psychiatry. 2015;14:339-347. doi: 10.1002/wps.20252

 

  1. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752. doi: 10.1161/circulationaha.105.169404

 

  1. Hagi K, Nosaka T, Dickinson D, et al. Association between cardiovascular risk factors and cognitive impairment in people with schizophrenia: A systematic review and meta-analysis. JAMA Psychiatry. 2021;78:510-518. doi: 10.1001/jamapsychiatry.2021.0015

 

  1. Harrison S, Couture P, Lamarche B. Diet quality, saturated fat and metabolic syndrome. Nutrients. 2020;12:3232. doi: 10.3390/nu12113232

 

  1. Hsu CN, Hou CY, Hsu WH, Tain YL. Early-life origins of metabolic syndrome: Mechanisms and preventive aspects. Int J Mol Sci. 2021;22:11872. doi: 10.3390/ijms222111872

 

  1. Carli M, Kolachalam S, Longoni B, et al. Atypical antipsychotics and metabolic syndrome: From molecular mechanisms to clinical differences. Pharmaceuticals (Basel). 2021;14:238. doi: 10.3390/ph14030238

 

  1. Citrome L, Holt RI, Walker DJ, Hoffmann VP. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clin Drug Investig. 2011;31:455-482. doi: 10.2165/11589060-000000000-00000

 

  1. De Hert M, Schreurs V, Sweers K, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review. Schizophr Res. 2008;101:295-303. doi: 10.1016/j.schres.2008.01.028

 

  1. Zhang M, Chen J, Yin Z, Peng L. The association between depression and metabolic syndrome and its components: A bidirectional two-sample Mendelian randomization study. Transl Psychiatry. 2021;11:633. doi: 10.1038/s41398-021-01759-z

 

  1. Dregan A, Rayner L, Davis KAS, et al. Associations between depression, arterial stiffness, and metabolic syndrome among adults in the UK biobank population study: A mediation analysis. JAMA Psychiatry. 2020;77:598-606. doi: 10.1001/jamapsychiatry.2019.4712

 

  1. Wang J, Li L, Zhang Z, et al. Extracellular vesicles mediate the communication of adipose tissue with brain and promote cognitive impairment associated with insulin resistance. Cell Metab. 2022;34:1264-1279.e8. doi: 10.1016/j.cmet.2022.08.004

 

  1. Wajngarten M, Silva GS. Hypertension and stroke: Update on treatment. Eur Cardiol. 2019;14:111-115. doi: 10.15420/ecr.2019.11.1

 

  1. Anjum S, Bathla M, Panchal S, Singh GP, Singh M. Metabolic syndrome in drug naïve schizophrenic patients. Diabetes Metab Syndr. 2018;12:135-140. doi: 10.1016/j.dsx.2017.11.006

 

  1. Enez Darcin A, Yalcin Cavus S, Dilbaz N, Kaya H, Dogan E. Metabolic syndrome in drug-naïve and drug-free patients with schizophrenia and in their siblings. Schizophr Res. 2015;166:201-206. doi: 10.1016/j.schres.2015.05.004

 

  1. Chen DC, Du XD, Yin GZ, et al. Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia: Relationships with clinical phenotypes and cognitive deficits. Psychol Med. 2016;46:3219-3230. doi: 10.1017/s0033291716001902
Share
Back to top
Journal of Clinical and Basic Psychosomatics, Electronic ISSN: 2972-4414 Print ISSN: 3060-8562, Published by AccScience Publishing
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept